Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsSolomon Langermann
Assistant Professor AdjunctAbout
Research
Publications
2025
NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression.
Giridharan T, Suzuki S, Khan A, Liu Q, Attwood K, Stokolosa A, Mahan S, Witkiewicz A, Joseph J, Moysich K, Langermann S, Lovewell R, Flies D, Myint H, Odunsi K, Emmons T, Yaffe M, Zsiros E, Dey P, McGray A, Segal B. NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression. The Journal Of Immunology 2025, 214: 2464-2479. PMID: 40560129, DOI: 10.1093/jimmun/vkaf121.Peer-Reviewed Original ResearchOvarian cancerLAIR-2Immune cellsOverall survivalTumor cellsAssociated with better OSAssociated with worse overall survivalHigh-grade serous ovarian cancerNon-small cell lung cancerSingle-center retrospective analysisTumor-infiltrating immune cellsT-cell suppressor functionLAIR-1Stromal immune cellsT-cell non-responsivenessEpithelial ovarian cancerT cell suppressionSerous ovarian cancerCell lung cancerImmune cell infiltrationT cell proliferationT cell membraneOptimal debulkingMalignant effusionsAdvanced OCA LAIR-1 targeting antibody drug conjugate for hematologic cancers.
Flies D, Barbu E, Kothari P, Kahan S, Maloveste S, Wilcox R, Kim T, Guha U, Langermann S, Panneer Selvam S, Lovewell R. A LAIR-1 targeting antibody drug conjugate for hematologic cancers. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e15022.Peer-Reviewed Original ResearchAntibody drug conjugatesLAIR-1 expressionLAIR-1Hematological cancersTumor cellsKnock-in (KI) miceControl of tumorsDrug conjugatesT-cell lymphomaHematopoietic cell subsetsImmune cell populationsKilling of leukemic cellsRegulate immune activationAnti-tumor activityExpressed high levelsLeukemic cell deathInternalization in vitroIn vitro cytotoxicity assayLymphoma tumorsTumor cell linesCell subsetsImmune activationLymphoma cellsLymphomaTumor modelA phase 1 dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors.
Song M, Tolcher A, Gutierrez M, Zsiros E, Fu S, Liu J, Morgensztern D, Kordahi S, Nietubicz C, Barbu E, Morawski A, Kahan S, Kothari P, Flies D, Panneer Selvam S, Slocum S, Ruiz-Soto R, Langermann S, Guha U, Mahadevan D. A phase 1 dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps3167.Peer-Reviewed Original ResearchAntibody drug conjugatesAnti-tumor activityB7-H4B7-H4 expressionMonomethyl auristatin ETumor typesDose expansionDose escalationRECIST v1.1Solid tumorsAntibody drug conjugate therapyNonhuman primate toxicity studiesPhase 1 dose-escalationRecommended phase 2 doseFc receptor-expressing cellsFirst-in-human studyBayesian optimal intervalDose-expansion studyPhase 2 doseXenograft in vivo modelDrug conjugatesMaximum tolerated doseBiliary tract cancerOff-target toxicityMultiple tumor typesImmune inhibitory receptor agonist therapeutics
Lovewell R, Langermann S, Flies D. Immune inhibitory receptor agonist therapeutics. Frontiers In Immunology 2025, 16: 1566869. PMID: 40207220, PMCID: PMC11979287, DOI: 10.3389/fimmu.2025.1566869.Peer-Reviewed Original ResearchConceptsAgonist suppressionSurface of immune cellsCheckpoint inhibitorsStimulatory cellsStimulatory receptorsSuppressive cellsDysregulated inflammationImmune cellsPre-clinicalTreat diseasesDisease settingsAgonistsImmune systemImmune pathwaysClinical therapeuticsTherapeutic interventionsDiseaseReceptorsCellular levelTherapeuticsCellsPathwayInduced signalsAutoimmunityInflammation
2024
632 NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naïve MSS/MSI-L colorectal cancer (CRC)
Barbu A, Kothari P, Kahan S, Christenson E, Kazmi S, Manda S, Chisamore M, Kordahi S, Martz A, Nelson M, Morawski A, Flies D, Langermann S, Guha U, Myint H. 632 NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naïve MSS/MSI-L colorectal cancer (CRC). 2024, a727-a727. DOI: 10.1136/jitc-2024-sitc2024.0632.Peer-Reviewed Original Research577P Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients
Christenson E, Kazmi S, Mahadevan D, Sohal D, Manda S, Martz A, Kordahi S, Zika M, Kothari P, Kahan S, Barbu E, Morawski A, Flies D, Langermann S, Chisamore M, Fu S, Wadlow R, Guha U, Myint H, Le D. 577P Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients. Annals Of Oncology 2024, 35: s468. DOI: 10.1016/j.annonc.2024.08.646.Peer-Reviewed Original Research758P Results of the phase Ib study of NC410 combined with pembrolizumab in ovarian cancer patients
Zsiros E, Christenson E, Sohal D, Manda S, Fu S, Martz A, Zika M, Kordahi S, Kothari P, Kahan S, Barbu E, Morawski A, Flies D, Langermann S, Chisamore M, Guha U, Myint H, Mahadevan D. 758P Results of the phase Ib study of NC410 combined with pembrolizumab in ovarian cancer patients. Annals Of Oncology 2024, 35: s575. DOI: 10.1016/j.annonc.2024.08.819.Peer-Reviewed Original ResearchBCAM (basal cell adhesion molecule) protein expression in different tumor populations
Burela S, He M, Trontzas I, Gavrielatou N, Schalper K, Langermann S, Flies D, Rimm D, Aung T. BCAM (basal cell adhesion molecule) protein expression in different tumor populations. Discover Oncology 2024, 15: 381. PMID: 39207605, PMCID: PMC11362396, DOI: 10.1007/s12672-024-01244-1.Peer-Reviewed Original ResearchPD-L1 expressionBasal cell adhesion moleculePD-L1Quantitative immunofluorescenceAssociated with better OSPD-L1 protein expressionCancer typesBladder urothelial tumorsProtein expressionMultiple immune checkpointsHead and neckMultiple tumor typesEvidence of hypermethylationImmune checkpointsImmunotherapy responseCell adhesion moleculesTumor typesValidation cohortTumor populationCancer patientsTumorPredictive valueAdhesion moleculesNovel biomarkersWidespread expressionA phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.
Christenson E, Mahadevan D, Kazmi S, Manda S, Sohal D, Hutson T, Fu S, Martz A, Kordahi S, Barbu E, Flies D, Langermann S, Chisamore M, Gutierrez M, Matrana M, Spira A, Wadlow R, Guha U, Myint H, Le D. A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer. Journal Of Clinical Oncology 2024, 42: 2538-2538. DOI: 10.1200/jco.2024.42.16_suppl.2538.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune cell infiltrationOvarian cancerColorectal cancerICI therapyCell infiltrationAdvanced metastatic colorectal cancerPromote immune cell infiltrationResistance to ICI therapyEffector memory T cellsPeripheral blood immunophenotypingPhase 1b/2 studyDose of pembrolizumabData cut-offMetastatic colorectal cancerMetastatic solid tumorsMemory T cellsColorectal cancer subjectsImmune cell functionHuman IgG1 Fc domainAnti-tumor activityTumor extracellular matrixModified toxicity probability intervalExtracellular matrixCheckpoint inhibitorsThe FLRT3-UNC5B Pathway is a Novel Regulator of T Immunosurveillance
Flies D, Yan C, Yang Q, Arbitman S, Fitzgerald D, Sharee S, Shaik J, Bosiacki J, Myers K, Paucarmayta A, Johnson D, O'Neill T, Cusumano Z, Langermann S, Langenau D, Patel S. The FLRT3-UNC5B Pathway is a Novel Regulator of T Immunosurveillance. The Journal Of Immunology 2024, 212: 0298_5492-0298_5492. DOI: 10.4049/jimmunol.212.supp.0298.5492.Peer-Reviewed Original ResearchT cell activationT cellsCell-derived xenograftsTumor growthT cell anti-tumor immunityInhibitor of T cell activationCell-derived xenograft modelControl T cell responsesHuman T cell functionT cell checkpointsAnti-tumor immunityT cell responsesT cell functionActivated T cellsTumor-immune interactionsPromote tumor growthHuman T cellsCAR-TUNC-5 netrin receptor BZebrafish tumor modelTumor cellsTumor modelReceptor BGain-of-function screenMonoclonal antibodies